Aime T Franco1, Julio C Ricarte-Filho1, Amber Isaza1, Zachary Jones1,2, Neil Jain1, Sogol Mostoufi-Moab1,3, Lea Surrey4, Theodore W Laetsch3, Marilyn M Li4, Jessica Clague DeHart5, Erin Reichenberger6, Deanne Taylor6, Ken Kazahaya7,8, N Scott Adzick8, Andrew J Bauer1. 1. Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA. 2. Deceased. 3. Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA. 4. Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA. 5. School of Community and Global Health, Claremont Graduate University, Claremont, CA. 6. Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA. 7. Division of Pediatric Otolaryngology, Children's Hospital of Philadelphia, Philadelphia, PA. 8. Department of Surgery, Children's Hospital of Philadelphia, Philadelphia, PA.
Abstract
PURPOSE: In 2014, data from a comprehensive multiplatform analysis of 496 adult papillary thyroid cancer samples reported by The Cancer Genome Atlas project suggested that reclassification of thyroid cancer into molecular subtypes, RAS-like and BRAF-like, better reflects clinical behavior than sole reliance on pathologic classification. The aim of this study was to categorize the common oncogenic variants in pediatric differentiated thyroid cancer (DTC) and investigate whether mutation subtype classification correlated with the risk of metastasis and response to initial therapy in pediatric DTC. METHODS: Somatic cancer gene panel analysis was completed on DTC from 131 pediatric patients. DTC were categorized into RAS-mutant (H-K-NRAS), BRAF-mutant (BRAF p.V600E), and RET/NTRK fusion (RET, NTRK1, and NTRK3 fusions) to determine differences between subtype classification in regard to pathologic data (American Joint Committee on Cancer TNM) as well as response to therapy 1 year after initial treatment had been completed. RESULTS: Mutation-based subtype categories were significant in most variables, including age at diagnosis, metastatic behavior, and the likelihood of remission at 1 year. Patients with RET/NTRK fusions were significantly more likely to have advanced lymph node and distant metastasis and less likely to achieve remission at 1 year than patients within RAS- or BRAF-mut subgroups. CONCLUSION: Our data support that genetic subtyping of pediatric DTC more accurately reflects clinical behavior than sole reliance on pathologic classification with patients with RET/NTRK fusions having worse outcomes than those with BRAF-mutant disease. Future trials should consider inclusion of molecular subtype into risk stratification.
PURPOSE: In 2014, data from a comprehensive multiplatform analysis of 496 adult papillary thyroid cancer samples reported by The Cancer Genome Atlas project suggested that reclassification of thyroid cancer into molecular subtypes, RAS-like and BRAF-like, better reflects clinical behavior than sole reliance on pathologic classification. The aim of this study was to categorize the common oncogenic variants in pediatric differentiated thyroid cancer (DTC) and investigate whether mutation subtype classification correlated with the risk of metastasis and response to initial therapy in pediatric DTC. METHODS: Somatic cancer gene panel analysis was completed on DTC from 131 pediatric patients. DTC were categorized into RAS-mutant (H-K-NRAS), BRAF-mutant (BRAF p.V600E), and RET/NTRK fusion (RET, NTRK1, and NTRK3 fusions) to determine differences between subtype classification in regard to pathologic data (American Joint Committee on Cancer TNM) as well as response to therapy 1 year after initial treatment had been completed. RESULTS: Mutation-based subtype categories were significant in most variables, including age at diagnosis, metastatic behavior, and the likelihood of remission at 1 year. Patients with RET/NTRK fusions were significantly more likely to have advanced lymph node and distant metastasis and less likely to achieve remission at 1 year than patients within RAS- or BRAF-mut subgroups. CONCLUSION: Our data support that genetic subtyping of pediatric DTC more accurately reflects clinical behavior than sole reliance on pathologic classification with patients with RET/NTRK fusions having worse outcomes than those with BRAF-mutant disease. Future trials should consider inclusion of molecular subtype into risk stratification.
Authors: Sujay Kakarmath; Howard T Heller; Caroline A Alexander; Edmund S Cibas; Jeffrey F Krane; Justine A Barletta; Neal I Lindeman; Mary C Frates; Carol B Benson; Atul A Gawande; Nancy L Cho; Matthew Nehs; Francis D Moore; Ellen Marqusee; Mathew I Kim; P Reed Larsen; Norra Kwong; Trevor E Angell; Erik K Alexander Journal: J Clin Endocrinol Metab Date: 2016-09-30 Impact factor: 5.958
Authors: Lea F Surrey; Suzanne P MacFarland; Fengqi Chang; Kajia Cao; Komal S Rathi; Gozde T Akgumus; Daniel Gallo; Fumin Lin; Adam Gleason; Pichai Raman; Richard Aplenc; Rochelle Bagatell; Jane Minturn; Yael Mosse; Mariarita Santi; Sarah K Tasian; Angela J Waanders; Mahdi Sarmady; John M Maris; Stephen P Hunger; Marilyn M Li Journal: Genome Med Date: 2019-05-28 Impact factor: 11.117
Authors: Michael V Ortiz; Ulrike Gerdemann; Sandya Govinda Raju; Dahlia Henry; Steve Smith; S Michael Rothenberg; Michael C Cox; Stéphanie Proust; Julia Glade Bender; A Lindsay Frazier; Peter Anderson; Alberto S Pappo Journal: JCO Precis Oncol Date: 2020-04-14
Authors: Victoria Casado-Medrano; Alison O'Neill; Stephen Halada; Theodore W Laetsch; Andrew J Bauer; Aime T Franco Journal: Cancer Genet Date: 2022-03-06
Authors: Sasha R Howard; Sarah Freeston; Barney Harrison; Louise Izatt; Sonali Natu; Kate Newbold; Sabine Pomplun; Helen A Spoudeas; Sophie Wilne; Tom R Kurzawinski; Mark N Gaze Journal: Endocr Relat Cancer Date: 2022-09-07 Impact factor: 5.900